Madrigal Secures Major Deal to Battle Liver Disease

A Chinese biotech company in Suzhou has given an American firm the worldwide rights to create and sell six new RNA medicines aimed at a serious liver condition. The deal brings an upfront cash payment of $60 million and could grow to nearly $4. 5 billion if the medicines reach several key development, approval and sales checkpoints. The Chinese partner will also earn a share of the profits from future product sales.This partnership focuses on therapies for metabolic dysfunction‑associated steatohepatitis, a disease that can lead to scarring of the liver, organ failure, cancer and early death if untreated. The agreement shows how international collaboration can speed up the journey from lab discovery to treatments that patients need. It also highlights the growing importance of RNA‑based medicines in tackling complex metabolic disorders. The arrangement is expected to accelerate research and bring new options to patients worldwide, while providing both companies with a clear financial roadmap for success.